簡體|繁體
Xalatan Latanoprost Eye Drops
Specification
0.005%(2.5ml:125μg)
Introduction

Xalatan is the first PG eyedrops launched on the market in the world by Pfizer. It is also the first-line drug for the treatment of glaucoma in most of the countries and regions. Essex Medipharma is responsible for the promotion and sale of the product in the mainland China.

Mechanism

The active ingredient latanoprost is the analogue of prostaglandin F2, which is a selective prostaglandin FP receptor agonist that can reduce intraocular pressure by enhancing the outflow of aqueous humor. For human being, the intraocular pressure (IOP) starts to drop down 3 or 4 hours later after drug administration, and the maximum effect can be achieved 8 to 12 hours later. Intraocular pressure reduction effect can last at least 24 hours. Studies on animals and human showed that the main action mechanism of the drug is to increase the bypass flow of uveoscleral of aqueous humor, but its benefit to the outflow of aqueous humor in human eyes by reducing the drainage resistance was also reported.

Features

The first line drug recommended by the guidelines in many countries;
Reducing intraocular pressure over 25%;
IOP meets standard for 24 hours after drug administration;
The first PG drug with the largest prescription in the world;
High medication persistence rate, as 81.6% of patients can adhere to medication for two years.

Application

The product is indicated for the reduction of elevated IOP of patients with open-angle glaucoma and ocular hypertension.

网上购买彩票 巴西对阵比利时比分预测 奥运球探比分直播 北京十一选五5开奖 可以赢红包的麻将 福彩3d排列三过滤工具 雪缘园nba即时比分 重庆幸运农场彩票夜场 河北十一选五 幸运飞艇八码计划图 黑龙江22选5玩法 皇冠比分足球 上海时时彩计划软件 新疆35选7走势图 皇冠比分ccrr22投注网 全天幸运飞艇开奖计划 山东十一选五的走势